WO2009134585A1 - System and method of determining arterial blood pressure and ventricular fill parameters from ventricular blood pressure waveform data - Google Patents

System and method of determining arterial blood pressure and ventricular fill parameters from ventricular blood pressure waveform data Download PDF

Info

Publication number
WO2009134585A1
WO2009134585A1 PCT/US2009/039402 US2009039402W WO2009134585A1 WO 2009134585 A1 WO2009134585 A1 WO 2009134585A1 US 2009039402 W US2009039402 W US 2009039402W WO 2009134585 A1 WO2009134585 A1 WO 2009134585A1
Authority
WO
WIPO (PCT)
Prior art keywords
pressure
ventricular
medical device
implantable medical
estimated
Prior art date
Application number
PCT/US2009/039402
Other languages
French (fr)
Inventor
Mustafa Karamanoglu
Tommy D. Bennett
Original Assignee
Medtronic, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medtronic, Inc. filed Critical Medtronic, Inc.
Priority to EP09739387A priority Critical patent/EP2192853A1/en
Publication of WO2009134585A1 publication Critical patent/WO2009134585A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/02Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A61B5/021Measuring pressure in heart or blood vessels
    • A61B5/0215Measuring pressure in heart or blood vessels by means inserted into the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/02Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A61B5/02028Determining haemodynamic parameters not otherwise provided for, e.g. cardiac contractility or left ventricular ejection fraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/02Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A61B5/021Measuring pressure in heart or blood vessels
    • A61B5/02108Measuring pressure in heart or blood vessels from analysis of pulse wave characteristics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/72Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7235Details of waveform analysis
    • A61B5/7239Details of waveform analysis using differentiation including higher order derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/362Heart stimulators
    • A61N1/365Heart stimulators controlled by a physiological parameter, e.g. heart potential
    • A61N1/36514Heart stimulators controlled by a physiological parameter, e.g. heart potential controlled by a physiological quantity other than heart potential, e.g. blood pressure
    • A61N1/36564Heart stimulators controlled by a physiological parameter, e.g. heart potential controlled by a physiological quantity other than heart potential, e.g. blood pressure controlled by blood pressure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/24Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
    • A61B5/316Modalities, i.e. specific diagnostic methods
    • A61B5/318Heart-related electrical modalities, e.g. electrocardiography [ECG]
    • A61B5/346Analysis of electrocardiograms
    • A61B5/349Detecting specific parameters of the electrocardiograph cycle
    • A61B5/352Detecting R peaks, e.g. for synchronising diagnostic apparatus; Estimating R-R interval

Definitions

  • the present invention relates to hemodynamic monitoring devices and methods.
  • the invention relates to a determination of blood pressure in pulmonary and systemic arteries and derivation of ventricular fill parameters based upon measurements of pressure within chambers of the heart.
  • the blood pressure in the pulmonary arteries and systemic arteries is important for assessing function of the heart, diagnosing hypertension, titrating drug treatment, and treating patients and animals under a wide variety of pathological and physiological conditions. If blood pressure measurements are done within chambers of the heart, the absolute diastolic pressures in the arteries can be difficult to estimate.
  • Systems and methods have been developed to derive an estimated pulmonary artery diastolic pressure (ePAD) based upon ventricular pressure measured within the right ventricle.
  • the ePAD pressure has been determined as being equal to the right ventricular pressure signal amplitude at the time of the maximum rate of rise in right ventricular pressure (dP/dt max ).
  • the ePAD pressure value can then be used, along with an estimated systolic pressure corresponding to the peak right ventricular pressure, to derive other estimated values, such as mean pulmonary artery pressure (MPAP).
  • MPAP mean pulmonary artery pressure
  • Hemodynamic monitoring devices and methods that measure ventricular blood pressure can use sensed blood pressure during a fill portion of the ventricular blood pressure waveform following peak pressure to derive hemodynamic parameters. These hemodynamic parameters may include estimated parameters relating to the pulmonary artery or the aorta, as well as parameters relating to ventricular fill characteristics.
  • the present invention is based upon the discovery that diastolic pressure in the pulmonary artery (PAD) or in the aorta (AoD) can be estimated by the ventricular pressure at the time that the time rate of change of ventricular pressure is at a peak minimum (dP/dt mm ).
  • PAD pulmonary artery
  • AoD aorta
  • an estimation of arterial diastolic pressure is made using sensed ventricular pressure by producing a ventricular pressure waveform, deriving a first derivative of the ventricular pressure waveform, and deriving an estimated arterial diastolic pressure based upon ventricular pressure amplitude at the time at which dP/dt is a peak minimum.
  • ePAD pulmonary artery diastolic
  • eAOD estimated aortic diastolic
  • the present invention makes use of pressure measurements that occur between dP/dt mm and a next occurrence of a beginning of a new ventricular pumping cycle (such as an R- wave). Pressure values are derived from the waveform representing a minimum ventricular pressure, a ventricular end diastolic pressure, and a diastasis pressure. From those pressure values, other parameters may be derived, including an isovolumetric relaxation time constant, a ventricular suction pressure, an atrial kick pressure, and a transvalve gradient pressure.
  • hemodynamic parameters are derived from pressure measurements made within the left ventricle.
  • the parameters include estimated aortic systolic, diastolic, and mean pressures, pre-ejection interval, systolic time interval, ejection duration, and left ventricular filling parameters.
  • FIG. 1 is a block diagram of an implantable medical device for measuring ventricular pressure and deriving blood pressure data related to pulmonary or systemic arteries, as well as ventricular filling parameters.
  • FIG. 2 is a diagram showing electrogram (EGM), arterial pressure (AP), ventricular pressure (VP), and first derivative (dP/dt) waveforms.
  • FIG. 3 shows the EGM, AP, VP, and dP/dt waveforms of FIG. 2 on a larger scale with associated fiducial points and derived hemodynamic parameters identified.
  • FIG. 4 A shows measured aortic diastolic pressure versus estimated aortic diastolic pressure based upon left ventricular pressure at dP/dt max .
  • FIG. 4B shows measured aortic diastolic pressure versus estimated aortic diastolic pressure based upon left ventricular pressure at dP/dt mm .
  • FIG. 5 A is a graph showing estimated pulmonary artery diastolic pressure based upon right ventricular pressure at dP/dt max versus measured pulmonary artery diastolic pressure.
  • FIG. 5B shows estimated pulmonary artery diastolic pressure based upon right ventricular pressure at dP/dtmm versus measured pulmonary diastolic pressure.
  • FIG. 1 is a block diagram of implantable medical device (IMD) 10 for chronically monitoring cardiac performance in a patient.
  • IMD 10 includes pressure sensor 12, electrogram (EGM) sensor 14, input circuit 16, processor 18, memory 20, telemetry circuit 22, and therapy delivery circuit 24.
  • EGM electrogram
  • Pressure sensor 12 is located inside either the right ventricle or the left ventricle of a patient's heart to sense blood pressure.
  • EGM sensor 14 is located in or near the heart to sense electrical activity of the heart.
  • Input circuit 16 is the signal processing circuit that receives pressure signal representative of blood pressure in the ventricle as a function of time from pressure sensor 12, and receives an electrical signal representative of electrical activity of the heart as a function of time from EGM sensor 14. Input circuit 16 may sample, demodulate, or otherwise process the signals received from pressure sensor 12 and EGM sensor 14. From these processed pressure and EMG signals received from input circuit 16, processor 18 derives several f ⁇ ducials and hemodynamic parameters. The hemodynamic parameters may be stored at processor 18 in memory 20 on a beat-by-beat basis, minute -to-minute basis, hour-to-hour basis, or some other basis.
  • Memory 20 may also include nonvolatile memory used to store code used to define the functions performed by processor 18, as well as configuration data used by processor 18.
  • Processor 18 may communicate the derived hemodynamic parameters externally through telemetry circuit 22.
  • Processor 18 may also receive information from a user, such as a physician or other medical personnel, through telemetry circuit 22.
  • IMD 10 delivers therapy in addition to monitoring hemodynamic parameters.
  • Processor 18 may provide the therapy control signal to therapy delivery circuit 24 to adjust or titrate any of the various therapies being administered to the patient based upon the hemodynamic parameters derived.
  • FIG. 2 is a diagram showing an electrogram (EGM) waveform, an arterial pressure (AP) waveform, a ventricular pressure (VP) waveform, and a first derivative (dP/dt) waveform.
  • the VP waveform can be generated by pressure sensor 12 located in either the patient's right ventricle or left ventricle.
  • the EGM waveform is produced by EGM sensor 14.
  • Either input circuit 16, or processor 18 can produce the dP/dt waveform by taking the first derivative of the VP waveform.
  • the arterial pressure AP waveform is not directly sensed, and is not available to processor 18. However, estimates of arterial systolic pressure ASP, diastolic pressure ADP, and arterial mean pressure AMP can be derived by processor 18 using the EGM, VP, and dP/dt waveforms.
  • FIG. 3 is a diagram showing the EGM, AP, VP, and dP/dt waveforms of FIG. 2 on a larger scale. Also shown in FIG. 3 are associated fiducial points and derived hemodynamic parameters.
  • a first fiducial point is derived from the EGM waveform. It represents the occurrence of an R-wave.
  • the time interval between successive R- waves (RR) is also shown in FIG. 3.
  • a second fiducial point is the occurrence of the maximum value of dP/dt (dP/dt max ).
  • the dP/dt max fiducial point occurs during the rising portion of the VP waveform.
  • the time interval between the first fiducial point (an R-wave) and the second fiducial point (dP/dt max ) is the pre-ejection interval (PEI).
  • a third fiducial point occurs when dP/dt is a minimum (dP/dt mm ). This occurs on the trailing edge of the VP signal, after a peak ventricular pressure has been obtained.
  • the time from the first fiducial point to the third fiducial point represents the systolic time interval (STI) shown in FIG. 3.
  • the ejection duration (ED) is the time difference between the pre-ejection interval (PEI) and the systolic time interval (STI), or the time between the second fiducial point and the third fiducial point. All three parameters PEI, STI, and ED can be derived by processor 18 using the pressure waveform and the fiducials. As shown in FIG.
  • arterial systolic pressure is essentially the same as the ventricular systolic pressure.
  • An estimated systolic pressure (eAoSP) of the aorta can be defined as being equal to the maximum value of the left ventricular pressure.
  • An estimated systolic pressure of the pulmonary artery (ePASP) can be defined as being equal to the maximum value of the right ventricular pressure.
  • the second fiducial point (dP/dt max ) occurs close in time to the minimum of the arterial pressure (AP) waveform, which represents the arterial diastolic pressure.
  • FIG. 3 also shows that the ventricular pressure at the second fiducial point is relatively close to the arterial diastolic pressure. It is possible, therefore, to use ventricular pressure at the second fiducial point (dP/dt max ) as an estimated arterial diastolic pressure (PpEi). This is similar to use of right ventricular pressure at dP/dt max as an estimated pulmonary artery diastolic pressure (ePAD), as described, for example, in Bennett et al. US 2006/0094967; Bennett et al US 2006/0167361; and Mulligan et al. US Patent No. 6,865,419.
  • ePAD estimated pulmonary artery diastolic pressure
  • the arterial pressure (AP) waveform exhibits a pressure at the third fiducial point that is much higher than the diastolic pressure in the artery, which represents the minimum in the AP waveform. It has been discovered, however, that the use of ventricular pressure at the third fiducial point corresponding to dP/dt min (Ps ⁇ i) provides another accurate estimation of arterial diastolic pressure. This discovery applies to the estimation of both aortic diastolic pressure (AoDP) using a sensed left ventricular pressure waveform, or estimation of pulmonary artery diastolic pressure (PADP) using a sensed right ventricular pressure waveform.
  • AoDP aortic diastolic pressure
  • PADP pulmonary artery diastolic pressure
  • FIG. 4 A shows a plot showing the relationship of measured and estimated aortic pressure, where estimated aortic diastolic pressure (AoDP) was based upon left ventricular pressure (LVP PEI ) at the second fiducial point (dP/dt max ).
  • Measured aortic diastolic pressure (AoDP) is plotted along the vertical (Y) axis, and estimated aortic diastolic pressure (LVP PEI ) is plotted along the horizontal axis.
  • the position of each data point represents an LVP PEI and the corresponding ADP.
  • the coefficient b was -4.6 and the coefficient a was 1.34 where Y is the measured aortic diastolic pressure and X is estimated aortic diastolic pressure LVP PEI , which is derived using the second fiducial point dP/dt max .
  • LVP PEI estimated aortic diastolic pressure
  • FIG. 4B shows a similar plot showing the relationship between actual aortic diastolic pressure ADP and estimated aortic diastolic pressure eAOD based upon the left ventricular pressure at the third fiducial point dP/dt ⁇ n .
  • the coefficient b was 7.6 and the coefficient a was 1.
  • R 2 0.82 and P ⁇ 0.001.
  • the use of pressure at the third fiducial point dP/dtmm for LVP STI represents statistically a more accurate estimation of the actual aortic diastolic pressure AoDP.
  • FIGS. 5A and 5B show a similar result achieved by estimating pulmonary artery diastolic pressure using right ventricular pressure at dP/dt min and dP/dt max .
  • RVP PEI is plotted along the vertical (Y) axis, and measured pulmonary artery diastolic pressure is plotted along the horizontal (X) axis.
  • RVP PEI represents the right ventricular pressure at dP/dt max , which is the traditional way that estimated pulmonary artery diastolic pressure has been derived.
  • RVP PEI aPADP + b.
  • FIG. 5B shows a similar plot with RVP PEI along the vertical axis and actual pulmonary artery diastolic pressure PADP along the horizontal axis.
  • RVP STI aPADP + b.
  • R 2 0.82, which indicates that right ventricular pressure at the third fiducial point (RVP STI ) is a more accurate estimation of pulmonary artery diastolic pressure PADP.
  • ventricular pressure at the dP/dt min third fiducial point provides another accurate estimation of arterial (i.e. either pulmonary or aortic) diastolic pressure ADP.
  • an estimated arterial mean pressure eAMP can then be derived by processor 18 using estimated arterial systolic pressure eASP, estimated arterial diastolic pressure eADP, and intervals STI and RR.
  • eAMP eDP + (eSP - eDP) * STI/RR.
  • Processor 18 may also derive other hemodynamic values may be derived from pressure waveform data contained in the portion of the waveform following the pressure peak.
  • the time between third fiducial point dP/dV n and the first fiducial point representing the next R-wave represents a time period during which the ventricle is filling.
  • Processor 18 can derive, from the VP waveform between the third fiducial point and the following first fiducial point, parameters related to ventricular filling properties.
  • processor 18 uses the third fiducial point derived from the dP/dt waveform and the first fiducial point derived from the EGM waveform to define a fill portion of the ventricular pressure waveform which begins with the third fiducial point and ends with the next first fiducial point. Within that fill portion, processor 18 identifies a minimum pressure VP min and a ventricular end diastolic pressure VDP which corresponds to the ventricular pressure at the R-wave (first fiducial point).
  • Processor 18 also identifies a diastasis portion of the VP waveform by using the dP/dt waveform.
  • the diastasis portion is a portion of the VP waveform between VP m1n and VDP which the waveform is relatively flat. This corresponds to dP/dt being essentially zero.
  • the pressure during this diastasis portion can then be used along with VP mm and VDP to derive ventricular fill parameters.
  • the difference between Pdiastasis and VPmin is the ventricular suction pressure P SU ction.
  • VDP the difference between VDP and the diastasis pressure Pdiastasis represents the pressure contribution of the atrial kick P AK -
  • P AK the pressure contribution of the atrial kick
  • PAK VDP - Pdiastasis.
  • the mitral valve between the left atrium and the left ventricle opens and blood flows from the left atrium into the left ventricle.
  • the filling can be aided by suction of the left ventricle as well as pushing of the blood into the left ventricle by the left atrium (i.e. the atrial kick).
  • the use of parameters derived from the LVP waveform during the filling portion allows processor 18 to provide an indication of the amount of effort being generated, and whether that effort is ventricular suction or atrial pushing.
  • the left ventricle will require a greater amount of sucking in order to draw blood through the smaller orifice.
  • P suc tion can provide an indication of the amount of sucking effort being provided by the left ventricle, which may be related to condition of the mitral valve.
  • a large left atrial kick is an indication of high left atrial pressures occurring. This may provide an indicator of potential pulmonary edema.
  • processor 18 may determine that the left atrium is beating erratically by analyzing the filling parameters. This may be an indication that synchronization of the left atrium to the left ventricle filling is an issue, and that cardiac resynchronization may be needed.
  • Processor 18 can derive a transmural pressure gradient value based upon a difference between the left ventricular end diastolic pressure LVDP and the minimum left ventricular pressure LVPm 1n :
  • the transmural pressure gradient therefore, is equal to the sum of the ventricular suction Psuction and the atrial kick pressure P AK -
  • the tricuspid valve between the right atrium and the right ventricle opens and blood flows from the right atrium into the right ventricle.
  • the filling can be aided by suction of the right ventricle as well as pushing of the blood into the right ventricle by the right atrium (i.e. the atrial kick).
  • RVP waveform The use of parameters derived from the RVP waveform during the filling portion allows processor 18 to provide an indication of the amount of effort being generated, and whether that effort is ventricular suction or atrial pushing.
  • the right ventricle will require a greater amount of sucking in order to draw blood through the smaller orifice.
  • the value of P suc tion can provide an indication of the amount of sucking effort being provided by the right ventricle, which may be related to condition of the tricuspid valve.
  • a large right atrial kick is an indication of high right atrial pressures occurring. This may provide an indicator of potential central venous edema.
  • processor 18 may determine that the right atrium is beating erratically by analyzing the filling parameters. This may be an indication that synchronization of the right atrium to the right ventricle filling is an issue, and that AV resynchronization may be needed.
  • RVDP — RVPmin Psuction + P AK-
  • the transtrcuspid pressure gradient therefore, is equal to the sum of the right ventricular suction P SU ction and the right atrial kick pressure P AK -
  • Processor 18 may also make use of the ventricular pressure rise and decay, as indicated by dP/dt max and to provide an estimate of ventricle muscle performance. This information, together with a fill characteristics and the arterial pressure parameters derived can be stored and then reported via telemetry. In addition, if the parameters indicate a condition requiring medical intervention, an alarm can be provided through by sending a signal via telemetry to an external alarm device, or through an alarm (such as a sound or vibration transducer) associated with the IMD 10.
  • an alarm can be provided through by sending a signal via telemetry to an external alarm device, or through an alarm (such as a sound or vibration transducer) associated with the IMD 10.
  • the derived parameters can also be used to control therapy being delivered by IMD 10 to a patient. This may involve adjusting pacing therapy to one or more chambers of the heart, or may involve titrating drug treatment being delivered through an implanted pump that is a part of or associated with IMD 10.

Abstract

A system and method of determining hemodynamic parameters uses sensed ventricular blood pressure during a portion of ventricular pressure waveform following peak pressure. An estimated arterial diastolic pressure is based upon an amplitude of the sensed ventricular pressure corresponding to a time at which a first derivative of ventricular pressure as a function of time is at a minimum (dP/dtmin). Fill parameters such as isovolumetric relaxation constant, ventricular suction pressure, atrial kick pressure, and transvalve pressure gradient are derived from measured pressures representing minimum ventricular pressure, ventricular diastolic pressure, and diastasis pressure.

Description

SYSTEM AND METHOD OF DETERMINING ARTERIAL BLOOD PRESSURE AND VENTRICULAR FILL PARAMETERS FROM VENTRICULAR BLOOD
PRESSURE WAVEFORM DATA
BACKGROUND OF THE INVENTION
The present invention relates to hemodynamic monitoring devices and methods. In particular, the invention relates to a determination of blood pressure in pulmonary and systemic arteries and derivation of ventricular fill parameters based upon measurements of pressure within chambers of the heart.
The blood pressure in the pulmonary arteries and systemic arteries is important for assessing function of the heart, diagnosing hypertension, titrating drug treatment, and treating patients and animals under a wide variety of pathological and physiological conditions. If blood pressure measurements are done within chambers of the heart, the absolute diastolic pressures in the arteries can be difficult to estimate. Systems and methods have been developed to derive an estimated pulmonary artery diastolic pressure (ePAD) based upon ventricular pressure measured within the right ventricle. The ePAD pressure has been determined as being equal to the right ventricular pressure signal amplitude at the time of the maximum rate of rise in right ventricular pressure (dP/dtmax).
The ePAD pressure value can then be used, along with an estimated systolic pressure corresponding to the peak right ventricular pressure, to derive other estimated values, such as mean pulmonary artery pressure (MPAP). Systems using ePAD pressure values are described, for example, in Bennett et al. U.S. Published Application No. US 2006/0167361; Bennett et al. U.S. Published Application No. US 2006/0094967; Mulligan et al. U.S. Patent No. 6,865,419; Struble U.S. Patent No. 6,580,946; Kieval et al. U.S. Patent No. 5,626,623; and Carney U.S. Patent No. 5,368,040, each of which are hereby incorporated by reference in their entirety.
BRIEF SUMMARY OF THE INVENTION
Hemodynamic monitoring devices and methods that measure ventricular blood pressure can use sensed blood pressure during a fill portion of the ventricular blood pressure waveform following peak pressure to derive hemodynamic parameters. These hemodynamic parameters may include estimated parameters relating to the pulmonary artery or the aorta, as well as parameters relating to ventricular fill characteristics.
In another aspect, the present invention is based upon the discovery that diastolic pressure in the pulmonary artery (PAD) or in the aorta (AoD) can be estimated by the ventricular pressure at the time that the time rate of change of ventricular pressure is at a peak minimum (dP/dtmm). Based upon this discovery, an estimation of arterial diastolic pressure (ePAD or eAOD) is made using sensed ventricular pressure by producing a ventricular pressure waveform, deriving a first derivative of the ventricular pressure waveform, and deriving an estimated arterial diastolic pressure based upon ventricular pressure amplitude at the time at which dP/dt is a peak minimum. To derive estimated pulmonary artery diastolic (ePAD) pressure, right ventricular pressure is sensed. To derive estimated aortic diastolic (eAOD) pressure, left ventricular pressure is sensed. In another aspect, the present invention makes use of pressure measurements that occur between dP/dtmm and a next occurrence of a beginning of a new ventricular pumping cycle (such as an R- wave). Pressure values are derived from the waveform representing a minimum ventricular pressure, a ventricular end diastolic pressure, and a diastasis pressure. From those pressure values, other parameters may be derived, including an isovolumetric relaxation time constant, a ventricular suction pressure, an atrial kick pressure, and a transvalve gradient pressure.
In another aspect, hemodynamic parameters are derived from pressure measurements made within the left ventricle. The parameters include estimated aortic systolic, diastolic, and mean pressures, pre-ejection interval, systolic time interval, ejection duration, and left ventricular filling parameters.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a block diagram of an implantable medical device for measuring ventricular pressure and deriving blood pressure data related to pulmonary or systemic arteries, as well as ventricular filling parameters.
FIG. 2 is a diagram showing electrogram (EGM), arterial pressure (AP), ventricular pressure (VP), and first derivative (dP/dt) waveforms.
FIG. 3 shows the EGM, AP, VP, and dP/dt waveforms of FIG. 2 on a larger scale with associated fiducial points and derived hemodynamic parameters identified. FIG. 4 A shows measured aortic diastolic pressure versus estimated aortic diastolic pressure based upon left ventricular pressure at dP/dtmax.
FIG. 4B shows measured aortic diastolic pressure versus estimated aortic diastolic pressure based upon left ventricular pressure at dP/dtmm.
FIG. 5 A is a graph showing estimated pulmonary artery diastolic pressure based upon right ventricular pressure at dP/dtmax versus measured pulmonary artery diastolic pressure.
FIG. 5B shows estimated pulmonary artery diastolic pressure based upon right ventricular pressure at dP/dtmm versus measured pulmonary diastolic pressure.
DETAILED DESCRIPTION
FIG. 1 is a block diagram of implantable medical device (IMD) 10 for chronically monitoring cardiac performance in a patient. IMD 10 includes pressure sensor 12, electrogram (EGM) sensor 14, input circuit 16, processor 18, memory 20, telemetry circuit 22, and therapy delivery circuit 24.
Pressure sensor 12 is located inside either the right ventricle or the left ventricle of a patient's heart to sense blood pressure. EGM sensor 14 is located in or near the heart to sense electrical activity of the heart.
Input circuit 16 is the signal processing circuit that receives pressure signal representative of blood pressure in the ventricle as a function of time from pressure sensor 12, and receives an electrical signal representative of electrical activity of the heart as a function of time from EGM sensor 14. Input circuit 16 may sample, demodulate, or otherwise process the signals received from pressure sensor 12 and EGM sensor 14. From these processed pressure and EMG signals received from input circuit 16, processor 18 derives several fϊducials and hemodynamic parameters. The hemodynamic parameters may be stored at processor 18 in memory 20 on a beat-by-beat basis, minute -to-minute basis, hour-to-hour basis, or some other basis.
Memory 20 may also include nonvolatile memory used to store code used to define the functions performed by processor 18, as well as configuration data used by processor 18. Processor 18 may communicate the derived hemodynamic parameters externally through telemetry circuit 22. Processor 18 may also receive information from a user, such as a physician or other medical personnel, through telemetry circuit 22. In some embodiments, IMD 10 delivers therapy in addition to monitoring hemodynamic parameters. Processor 18 may provide the therapy control signal to therapy delivery circuit 24 to adjust or titrate any of the various therapies being administered to the patient based upon the hemodynamic parameters derived.
FIG. 2 is a diagram showing an electrogram (EGM) waveform, an arterial pressure (AP) waveform, a ventricular pressure (VP) waveform, and a first derivative (dP/dt) waveform. The VP waveform can be generated by pressure sensor 12 located in either the patient's right ventricle or left ventricle. The EGM waveform is produced by EGM sensor 14. Either input circuit 16, or processor 18 can produce the dP/dt waveform by taking the first derivative of the VP waveform. The arterial pressure AP waveform, however, is not directly sensed, and is not available to processor 18. However, estimates of arterial systolic pressure ASP, diastolic pressure ADP, and arterial mean pressure AMP can be derived by processor 18 using the EGM, VP, and dP/dt waveforms.
FIG. 3 is a diagram showing the EGM, AP, VP, and dP/dt waveforms of FIG. 2 on a larger scale. Also shown in FIG. 3 are associated fiducial points and derived hemodynamic parameters.
In FIG. 3, a first fiducial point is derived from the EGM waveform. It represents the occurrence of an R-wave. The time interval between successive R- waves (RR) is also shown in FIG. 3.
A second fiducial point is the occurrence of the maximum value of dP/dt (dP/dtmax). The dP/dtmax fiducial point occurs during the rising portion of the VP waveform.
The time interval between the first fiducial point (an R-wave) and the second fiducial point (dP/dtmax) is the pre-ejection interval (PEI).
A third fiducial point occurs when dP/dt is a minimum (dP/dtmm). This occurs on the trailing edge of the VP signal, after a peak ventricular pressure has been obtained. The time from the first fiducial point to the third fiducial point represents the systolic time interval (STI) shown in FIG. 3. The ejection duration (ED) is the time difference between the pre-ejection interval (PEI) and the systolic time interval (STI), or the time between the second fiducial point and the third fiducial point. All three parameters PEI, STI, and ED can be derived by processor 18 using the pressure waveform and the fiducials. As shown in FIG. 3, arterial systolic pressure (ASP) is essentially the same as the ventricular systolic pressure. An estimated systolic pressure (eAoSP) of the aorta can be defined as being equal to the maximum value of the left ventricular pressure. An estimated systolic pressure of the pulmonary artery (ePASP) can be defined as being equal to the maximum value of the right ventricular pressure.
As shown in FIG. 3, the second fiducial point (dP/dtmax) occurs close in time to the minimum of the arterial pressure (AP) waveform, which represents the arterial diastolic pressure. FIG. 3 also shows that the ventricular pressure at the second fiducial point is relatively close to the arterial diastolic pressure. It is possible, therefore, to use ventricular pressure at the second fiducial point (dP/dtmax) as an estimated arterial diastolic pressure (PpEi). This is similar to use of right ventricular pressure at dP/dtmax as an estimated pulmonary artery diastolic pressure (ePAD), as described, for example, in Bennett et al. US 2006/0094967; Bennett et al US 2006/0167361; and Mulligan et al. US Patent No. 6,865,419.
As shown in FIG. 3, the arterial pressure (AP) waveform exhibits a pressure at the third fiducial point that is much higher than the diastolic pressure in the artery, which represents the minimum in the AP waveform. It has been discovered, however, that the use of ventricular pressure at the third fiducial point corresponding to dP/dtmin(Psτi) provides another accurate estimation of arterial diastolic pressure. This discovery applies to the estimation of both aortic diastolic pressure (AoDP) using a sensed left ventricular pressure waveform, or estimation of pulmonary artery diastolic pressure (PADP) using a sensed right ventricular pressure waveform.
FIG. 4 A shows a plot showing the relationship of measured and estimated aortic pressure, where estimated aortic diastolic pressure (AoDP) was based upon left ventricular pressure (LVPPEI) at the second fiducial point (dP/dtmax). Measured aortic diastolic pressure (AoDP) is plotted along the vertical (Y) axis, and estimated aortic diastolic pressure (LVPPEI) is plotted along the horizontal axis. The position of each data point represents an LVPPEI and the corresponding ADP. The relationship shown in FIG. 4A is defined by the equation AoDP = aLVPpEi + b. By way of example, for this patient population, the coefficient b was -4.6 and the coefficient a was 1.34 where Y is the measured aortic diastolic pressure and X is estimated aortic diastolic pressure LVPPEI, which is derived using the second fiducial point dP/dtmax. As shown in FIG. 4A, a statistical analysis of the data yields R2 = 0.71, and P < 0.001.
FIG. 4B shows a similar plot showing the relationship between actual aortic diastolic pressure ADP and estimated aortic diastolic pressure eAOD based upon the left ventricular pressure at the third fiducial point dP/dt^n. The relationship is defined by ADP = aLVPsTi + b. By way of example, for this patient population the coefficient b was 7.6 and the coefficient a was 1. In this case, R2 = 0.82 and P < 0.001. Thus, the use of pressure at the third fiducial point dP/dtmm for LVP STI represents statistically a more accurate estimation of the actual aortic diastolic pressure AoDP.
FIGS. 5A and 5B show a similar result achieved by estimating pulmonary artery diastolic pressure using right ventricular pressure at dP/dtmin and dP/dtmax.
In FIG. 5A, RVPPEI is plotted along the vertical (Y) axis, and measured pulmonary artery diastolic pressure is plotted along the horizontal (X) axis. RVPPEI represents the right ventricular pressure at dP/dtmax, which is the traditional way that estimated pulmonary artery diastolic pressure has been derived. The relationship between the estimated and actual pulmonary artery diastolic pressure is shown by the relationship RVPPEI = aPADP + b. By way of example, for this patient population the coefficient b was 11.69 and the coefficient a was 0.6425. In this case, R2 = 0.62.
FIG. 5B shows a similar plot with RVPPEI along the vertical axis and actual pulmonary artery diastolic pressure PADP along the horizontal axis. The relationship is defined by RVPSTI = aPADP + b. By way of example, for this patient population the coefficient b was 7.775 and the coefficient a was 0.9095. In this case, R2 = 0.82, which indicates that right ventricular pressure at the third fiducial point
Figure imgf000007_0001
(RVPSTI) is a more accurate estimation of pulmonary artery diastolic pressure PADP.
As illustrated by both FIGS. 4A and 4B and FIGS. 5A and 5B, the use of ventricular pressure at the dP/dtmin third fiducial point provides another accurate estimation of arterial (i.e. either pulmonary or aortic) diastolic pressure ADP. In either case, an estimated arterial mean pressure eAMP can then be derived by processor 18 using estimated arterial systolic pressure eASP, estimated arterial diastolic pressure eADP, and intervals STI and RR. The relationship can be stated as: eAMP = eDP + (eSP - eDP) * STI/RR. Processor 18 may also derive other hemodynamic values may be derived from pressure waveform data contained in the portion of the waveform following the pressure peak. The time between third fiducial point dP/dVn and the first fiducial point representing the next R-wave represents a time period during which the ventricle is filling. Processor 18 can derive, from the VP waveform between the third fiducial point and the following first fiducial point, parameters related to ventricular filling properties. These include isovolumetric relaxation time constant tau ( ), ventricular suction Psuction, atrial kick pressure PAK, diastasis pressure Pdiastasis, and transmural pressure gradient Pmitrai- Processor 18 uses the third fiducial point derived from the dP/dt waveform and the first fiducial point derived from the EGM waveform to define a fill portion of the ventricular pressure waveform which begins with the third fiducial point and ends with the next first fiducial point. Within that fill portion, processor 18 identifies a minimum pressure VPmin and a ventricular end diastolic pressure VDP which corresponds to the ventricular pressure at the R-wave (first fiducial point). The pressure at dP/dtmm (PSTI) and at VDP can then be used along with dP/dtmin to derive the isovolumetric relaxation time constant tau ( ) as: = -(PSTI - VDP)/ dP/dW
Processor 18 also identifies a diastasis portion of the VP waveform by using the dP/dt waveform. The diastasis portion is a portion of the VP waveform between VPm1n and VDP which the waveform is relatively flat. This corresponds to dP/dt being essentially zero. The pressure during this diastasis portion (Pdiastasis) can then be used along with VPmm and VDP to derive ventricular fill parameters. The difference between Pdiastasis and VPmin is the ventricular suction pressure PSUction. In other words:
P L suction = P L d ,iastasis V v P L min-
The difference between VDP and the diastasis pressure Pdiastasis represents the pressure contribution of the atrial kick PAK- In other words:
PAK = VDP - Pdiastasis.
During the filling portion, the mitral valve between the left atrium and the left ventricle opens and blood flows from the left atrium into the left ventricle. The filling can be aided by suction of the left ventricle as well as pushing of the blood into the left ventricle by the left atrium (i.e. the atrial kick). The use of parameters derived from the LVP waveform during the filling portion allows processor 18 to provide an indication of the amount of effort being generated, and whether that effort is ventricular suction or atrial pushing.
If there is mitral stenosis, (i.e. the opening through the mitral valve is reduced), the left ventricle will require a greater amount of sucking in order to draw blood through the smaller orifice. Thus the value of Psuction can provide an indication of the amount of sucking effort being provided by the left ventricle, which may be related to condition of the mitral valve.
A large left atrial kick is an indication of high left atrial pressures occurring. This may provide an indicator of potential pulmonary edema. In another case, processor 18 may determine that the left atrium is beating erratically by analyzing the filling parameters. This may be an indication that synchronization of the left atrium to the left ventricle filling is an issue, and that cardiac resynchronization may be needed.
Processor 18 can derive a transmural pressure gradient value based upon a difference between the left ventricular end diastolic pressure LVDP and the minimum left ventricular pressure LVPm1n:
Pmitral = LVDP - LVP1111n = Psuctlon + PAK-
The transmural pressure gradient, therefore, is equal to the sum of the ventricular suction Psuction and the atrial kick pressure PAK-
During the filling portion, the tricuspid valve between the right atrium and the right ventricle opens and blood flows from the right atrium into the right ventricle. The filling can be aided by suction of the right ventricle as well as pushing of the blood into the right ventricle by the right atrium (i.e. the atrial kick).
The use of parameters derived from the RVP waveform during the filling portion allows processor 18 to provide an indication of the amount of effort being generated, and whether that effort is ventricular suction or atrial pushing.
If there is tricuspid stenosis, (i.e. the opening through the tricuspid valve is reduced), the right ventricle will require a greater amount of sucking in order to draw blood through the smaller orifice. Thus the value of Psuction can provide an indication of the amount of sucking effort being provided by the right ventricle, which may be related to condition of the tricuspid valve. A large right atrial kick is an indication of high right atrial pressures occurring. This may provide an indicator of potential central venous edema. In another case, processor 18 may determine that the right atrium is beating erratically by analyzing the filling parameters. This may be an indication that synchronization of the right atrium to the right ventricle filling is an issue, and that AV resynchronization may be needed.
Ptricuspid = RVDP — RVPmin = Psuction + P AK-
The transtrcuspid pressure gradient, therefore, is equal to the sum of the right ventricular suction PSUction and the right atrial kick pressure PAK-
Processor 18 may also make use of the ventricular pressure rise and decay, as indicated by dP/dtmax and
Figure imgf000010_0001
to provide an estimate of ventricle muscle performance. This information, together with a fill characteristics and the arterial pressure parameters derived can be stored and then reported via telemetry. In addition, if the parameters indicate a condition requiring medical intervention, an alarm can be provided through by sending a signal via telemetry to an external alarm device, or through an alarm (such as a sound or vibration transducer) associated with the IMD 10.
The derived parameters can also be used to control therapy being delivered by IMD 10 to a patient. This may involve adjusting pacing therapy to one or more chambers of the heart, or may involve titrating drug treatment being delivered through an implanted pump that is a part of or associated with IMD 10.
Although the present invention has been described with reference to preferred embodiments, workers skilled in the art will recognize that changes may be made in form and detail without departing from the spirit and scope of the invention.

Claims

WHAT IS CLAIMED IS:
1. An implantable medical device comprising: an input circuit that receives a pressure waveform signal representative of a pressure (P) sensed within a ventricle of a patient's heart as a function of time (t); and a processor that derives from the pressure waveform signal at least one hemodynamic parameter based upon at least one ventricular pressure value during a portion of the pressure waveform signal between a peak ventricular pressure and a beginning of a next ventricular pumping cycle.
2. The implantable medical device of claim 1, wherein the processor derives an estimated arterial diastolic pressure based upon pressure in the ventricle at a time corresponding to a maximum rate of pressure decline (dP/dtmm).
3. The implantable medical device of claim 1 and further comprising a blood pressure sensor located in the ventricle for providing the pressure waveform signal to the input circuit.
4. The implantable medical device of claim 3, wherein the blood pressure sensor is a right ventricular pressure sensor, and the estimated arterial diastolic pressure is an estimated pulmonary artery diastolic pressure.
5. The implantable medical device of claim 3, wherein the blood pressure sensor is a left ventricular pressure sensor, and the estimated arterial diastolic pressure is an estimated aortic diastolic pressure.
6. The implantable medical device of claim 1, wherein the input circuit also receives an electrical signal representative of electrical activity in the heart as a function of time.
7. The implantable medical device of claim 1, wherein the processor derives from the pressure waveform signal at least one ventricular fill parameter based upon pressure values during a fill portion between occurrence of dP/dt^ and the beginning of a next ventricular pumping cycle.
8. The implantable medical device of claim 7, wherein the processor derives at least one ventricular fill parameter by: producing a dP/dt waveform from the pressure signal; identifying a fill portion of the pressure waveform signal; identifying a diastasis portion of the fill portion using the dP/dt waveform; and deriving a diastasis pressure representing the ventricular pressure in the diastasis portion of the pressure waveform signal.
9. The implantable medical device of claim 7, wherein the processor determines from the fill portion of the pressure waveform signal a ventricular diastolic pressure, a minimum ventricular pressure, and a diastasis pressure.
10. The implantable medical device of claim 9 wherein the processor derives an atrial kick parameter based upon a difference between the ventricular end diastolic pressure and the diastasis pressure.
11. The implantable medical device of claim 9, wherein the processor derives a ventricular suction parameter based upon a difference between the diastasis ventricular pressure and the minimum ventricular pressure.
12. The implantable medical device of claim 9, wherein the processor derives a transvalve pressure gradient parameter based upon a difference between the ventricular diastolic pressure and the minimum ventricular pressure.
13. The implantable medical device of claim 1, wherein the process derives an isovolumetric relaxation constant based upon dP/dVn, a ventricular pressure at dP/dt^ (P STi), and a ventricular pressure at occurrence of an R- wave (VDP).
14. An implantable medical device according to any of the above claims, wherein the input circuit receives a pressure waveform signal representative of a pressure (LVP) sensed within a left ventricle of a patient's heart as a function of time (t); and the processor derives the hemodynamic parameter based upon the representative signal.
15. The implantable medical device of claim 14, wherein the processor derives an estimated aortic diastolic pressure based upon at least one of (a) pressure in the left ventricle at a time corresponding to a maximum rate of pressure increase (dP/dtmax), and (b) pressure in the left ventricle at a time corresponding to a maximum rate of pressure decline (dP/dtmm).
16. The implantable medical device of claim 14, wherein the processor derives an estimated aortic systolic pressure based upon a peak pressure in the left ventricle.
17. The implantable medical device of claim 14, wherein the processor derives an estimated aortic mean pressure based upon the estimated aortic systolic pressure and the estimated aortic diastolic pressure.
18. The implantable medical device of claim 14, wherein the processor derives from the pressure waveform signal at least one of pre-ejection interval, systolic time interval, and an ejection duration.
PCT/US2009/039402 2008-04-30 2009-04-03 System and method of determining arterial blood pressure and ventricular fill parameters from ventricular blood pressure waveform data WO2009134585A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP09739387A EP2192853A1 (en) 2008-04-30 2009-04-03 System and method of determining arterial blood pressure and ventricular fill parameters from ventricular blood pressure waveform data

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/112,544 US8211028B2 (en) 2008-04-30 2008-04-30 System and method of determining arterial blood pressure and ventricular fill parameters from ventricular blood pressure waveform data
US12/112,544 2008-04-30

Publications (1)

Publication Number Publication Date
WO2009134585A1 true WO2009134585A1 (en) 2009-11-05

Family

ID=40759955

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/039402 WO2009134585A1 (en) 2008-04-30 2009-04-03 System and method of determining arterial blood pressure and ventricular fill parameters from ventricular blood pressure waveform data

Country Status (3)

Country Link
US (1) US8211028B2 (en)
EP (1) EP2192853A1 (en)
WO (1) WO2009134585A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011090552A1 (en) * 2009-12-30 2011-07-28 Medtronic, Inc. Optimization of av delay using ventricular pressure signal
WO2012015948A1 (en) * 2010-07-28 2012-02-02 Medtronic, Inc. Measurement of cardiac cycle length and pressure metrics from pulmonary arterial pressure
US8827913B2 (en) 2011-05-03 2014-09-09 Medtronic, Inc. Verification of pressure metrics
US9314205B2 (en) 2011-04-28 2016-04-19 Medtronic, Inc. Measurement of cardiac cycle length and pressure metrics from pulmonary arterial pressure

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10117982B2 (en) * 2016-04-15 2018-11-06 Guy P. Curtis And Frances L. Curtis Trust System and method for improving a heart muscle response
US10426962B2 (en) * 2016-07-07 2019-10-01 Cardiac Pacemakers, Inc. Leadless pacemaker using pressure measurements for pacing capture verification
US11020011B2 (en) * 2016-07-20 2021-06-01 Cardiac Pacemakers, Inc. Estimate diastolic pressure
JP7038115B2 (en) 2016-10-27 2022-03-17 カーディアック ペースメイカーズ, インコーポレイテッド Implantable medical device with pressure sensor
WO2019036600A1 (en) 2017-08-18 2019-02-21 Cardiac Pacemakers, Inc. Implantable medical device with pressure sensor
WO2024026493A2 (en) * 2022-07-28 2024-02-01 The Regents Of The University Of California Novel components for a hemodynamic analysis tool

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5368040A (en) 1993-08-02 1994-11-29 Medtronic, Inc. Apparatus and method for determining a plurality of hemodynamic variables from a single, chroniclaly implanted absolute pressure sensor
US5626623A (en) 1996-04-30 1997-05-06 Medtronic, Inc. Method and apparatus for optimizing pacemaker AV delay
US6580946B2 (en) 2001-04-26 2003-06-17 Medtronic, Inc. Pressure-modulated rate-responsive cardiac pacing
US20040167410A1 (en) 2003-02-26 2004-08-26 Medtronic, Inc. Methods and apparatus for estimation of ventricular afterload based on ventricular pressure measurements
US6865419B2 (en) 2000-12-01 2005-03-08 Medtronic, Inc. Method and apparatus for measurement of mean pulmonary artery pressure from a ventricle in an ambulatory monitor
US20060094967A1 (en) 2004-10-29 2006-05-04 Bennett Tommy D Method and apparatus to provide diagnostic index and therapy regulated by subject's autonomic nervous system
US20060167361A1 (en) 2005-01-27 2006-07-27 Bennett Tommy D Method and apparatus for continuous pulse contour cardiac output
US20070219591A1 (en) * 2003-01-24 2007-09-20 Mark Zdeblick Methods and apparatus for enhancing cardiac pacing

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7024244B2 (en) * 2002-04-22 2006-04-04 Medtronic, Inc. Estimation of stroke volume cardiac output using an intracardiac pressure sensor

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5368040A (en) 1993-08-02 1994-11-29 Medtronic, Inc. Apparatus and method for determining a plurality of hemodynamic variables from a single, chroniclaly implanted absolute pressure sensor
US5626623A (en) 1996-04-30 1997-05-06 Medtronic, Inc. Method and apparatus for optimizing pacemaker AV delay
US6865419B2 (en) 2000-12-01 2005-03-08 Medtronic, Inc. Method and apparatus for measurement of mean pulmonary artery pressure from a ventricle in an ambulatory monitor
US6580946B2 (en) 2001-04-26 2003-06-17 Medtronic, Inc. Pressure-modulated rate-responsive cardiac pacing
US20070219591A1 (en) * 2003-01-24 2007-09-20 Mark Zdeblick Methods and apparatus for enhancing cardiac pacing
US20040167410A1 (en) 2003-02-26 2004-08-26 Medtronic, Inc. Methods and apparatus for estimation of ventricular afterload based on ventricular pressure measurements
US20060094967A1 (en) 2004-10-29 2006-05-04 Bennett Tommy D Method and apparatus to provide diagnostic index and therapy regulated by subject's autonomic nervous system
US20060167361A1 (en) 2005-01-27 2006-07-27 Bennett Tommy D Method and apparatus for continuous pulse contour cardiac output

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2192853A1

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011090552A1 (en) * 2009-12-30 2011-07-28 Medtronic, Inc. Optimization of av delay using ventricular pressure signal
WO2012015948A1 (en) * 2010-07-28 2012-02-02 Medtronic, Inc. Measurement of cardiac cycle length and pressure metrics from pulmonary arterial pressure
US9241640B2 (en) 2010-07-28 2016-01-26 Medtronic, Inc. Measurement of cardiac cycle length and pressure metrics from pulmonary arterial pressure
US9254091B2 (en) 2010-07-28 2016-02-09 Medtronic, Inc. Measurement of cardiac cycle length and pressure metrics from pulmonary arterial pressure
US10226630B2 (en) 2010-07-28 2019-03-12 Medtronic, Inc. Measurement of cardiac cycle length and pressure metrics from pulmonary arterial pressure
US9314205B2 (en) 2011-04-28 2016-04-19 Medtronic, Inc. Measurement of cardiac cycle length and pressure metrics from pulmonary arterial pressure
US10362946B2 (en) 2011-04-28 2019-07-30 Medtronic, Inc. Measurement of cardiac cycle length and pressure metrics from pulmonary arterial pressure
US11399725B2 (en) 2011-04-28 2022-08-02 Medtronic, Inc. Measurement of cardiac cycle length and pressure metrics from pulmonary arterial pressure
US8827913B2 (en) 2011-05-03 2014-09-09 Medtronic, Inc. Verification of pressure metrics

Also Published As

Publication number Publication date
EP2192853A1 (en) 2010-06-09
US8211028B2 (en) 2012-07-03
US20090275843A1 (en) 2009-11-05

Similar Documents

Publication Publication Date Title
US8211028B2 (en) System and method of determining arterial blood pressure and ventricular fill parameters from ventricular blood pressure waveform data
US8591423B2 (en) Systems and methods for determining cardiac output using pulmonary artery pressure measurements
US7507208B2 (en) Method and apparatus for continuous pulse contour cardiac output
EP1079893B1 (en) Cardiac pacing using adjustable atrio-ventricular delays
EP2346401B1 (en) Heart failure detector
US7935062B2 (en) Derivation of flow contour from pressure waveform
US8755883B2 (en) Tracking progression of congestive heart failure via a force-frequency relationship
US8632470B2 (en) Assessment of pulmonary vascular resistance via pulmonary artery pressure
US20080300643A1 (en) Heart failure therapy adjustment based on ventricular pressures
US20020049478A1 (en) Cardiac pacing using adjustable atrio-ventricular delays
US20130012824A1 (en) Coronary venous system pressure sensing
US8702604B2 (en) Detection of waveform artifact
JPH0788199A (en) Rate adaptable type pacer which uses variation related to respiration in ventricle capacity or internal pressure as control parameter
US20090149766A1 (en) Coronary vein hemodynamic sensor
US20110034812A1 (en) Pulmonary artery pressure based systolic timing intervals as a measure of right ventricular systolic performance
WO2006081590A2 (en) System and method for monitoring myocardial performance using sensed ventricular pressures
EP1538979B1 (en) A congestive heart failure monitor
EP2303402A1 (en) Implantable heart stimulator determining left ventricular systolic pressure

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09739387

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009739387

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE